| Margaret Tallyn Rush, MD | |
|
25 Collins Rd, Bristol, CT 06010-3893 | |
| (860) 589-8882 | |
| (860) 585-8898 |
| Full Name | Margaret Tallyn Rush |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 16 Years |
| Location | 25 Collins Rd, Bristol, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063777282 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 55726 (Connecticut) | Primary |
| 208M00000X | Hospitalist | 55726 (Connecticut) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bristol Hospital | Bristol, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Prohealth Physicians Pc | 1355246950 | 236 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
In response to figures on alcohol abuse released this week, Dr Peter Rice, a leading consultant psychiatrist with the NHS Tayside Alcohol Problem Service, said he is not surprised as alcohol-related problems were having a detrimental effect on the lives of too many people across Tayside and Scotland.
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/245,607 ("the '607 Application").
› Verified 7 days ago
| Entity Name | Prohealth Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720194053 PECOS PAC ID: 1355246950 Enrollment ID: O20031205000602 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
In response to figures on alcohol abuse released this week, Dr Peter Rice, a leading consultant psychiatrist with the NHS Tayside Alcohol Problem Service, said he is not surprised as alcohol-related problems were having a detrimental effect on the lives of too many people across Tayside and Scotland.
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/245,607 ("the '607 Application").
› Verified 7 days ago
| Entity Name | Hartford Healthcare Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043561301 PECOS PAC ID: 1153573902 Enrollment ID: O20121201000007 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
In response to figures on alcohol abuse released this week, Dr Peter Rice, a leading consultant psychiatrist with the NHS Tayside Alcohol Problem Service, said he is not surprised as alcohol-related problems were having a detrimental effect on the lives of too many people across Tayside and Scotland.
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/245,607 ("the '607 Application").
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Margaret Tallyn Rush, MD 25 Collins Rd, Bristol, CT 06010-3893 Ph: (860) 589-8882 | Margaret Tallyn Rush, MD 25 Collins Rd, Bristol, CT 06010-3893 Ph: (860) 589-8882 |
News Archive
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
Sun Pharma today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the Eastern District of Michigan against Eli Lily and Co. finding certain claims of U.S. Patent No. 5,464,826 ("'826 patent") invalid. The appeal arose out of a lawsuit that Eli Lilly filed against Sun Pharma in connection with Sun Pharma's submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gemzar®.
In response to figures on alcohol abuse released this week, Dr Peter Rice, a leading consultant psychiatrist with the NHS Tayside Alcohol Problem Service, said he is not surprised as alcohol-related problems were having a detrimental effect on the lives of too many people across Tayside and Scotland.
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued a Notice of Allowance for U.S. Patent Application 13/245,607 ("the '607 Application").
› Verified 7 days ago
Dr. Vijai Brindaban Muthukrishnan, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25 Collins Rd, Bristol, CT 06010 Phone: 860-253-7236 | |
Katelin Ashley Bouchard, APRN Family Medicine Medicare: Medicare Enrolled Practice Location: 130 Collins Rd, Bristol, CT 06010 Phone: 860-919-5626 | |
Dr. Devorah Donnell, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 25 Collins Rd, Bristol, CT 06010 Phone: 860-589-8882 | |
Dr. Jeffrey R Goldberg, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25 Collins Road, Bristol, CT 06010 Phone: 860-589-8882 Fax: 860-585-8898 | |
Dr. Howard A Selinger, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25 Collins Rd, Bristol, CT 06010 Phone: 860-589-8882 Fax: 860-585-8898 | |
Dr. Lea Bailey, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25 Collins Rd, Bristol, CT 06010 Phone: 860-589-8882 Fax: 860-585-8898 |